Plitidepsin receives second negative recommendation across Europe

Plitidepsin (Aplidin®), a new medicine for the treatment of relapsed and refractory myeloma, has today received a second negative recommendation from the Committee for Medicinal Products for Human Use (CHMP). This decision means that plitidepsin is very unlikely to made available to patients across Europe. This upholds a previous negative recommendation from the CHMP, which was reviewed following an appeal by the pharmaceutical company Pharma Mar.

Myeloma Patients Europe (MPE) joins project consortium looking at the role of innovative CAR-T immunotherapy in multiple myeloma

Today marks the official launch of a new international project consortium, known as “CARAMBA”, which will research an innovative immunotherapy for the treatment of multiple myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide-range of stakeholders, the consortium aims to ensure the streamlined transition of CAR-T from the laboratory through to multiple myeloma patients in the clinic.

Open call for members to participate in patient information pilot (deadline Mon 12 February)

MPE is inviting members to express their interest in participating in a small pilot on patient information for newly diagnosed myeloma patients. As part of this pilot, MPE will be adapting and translating an Infopack for newly diagnosed patients (created by Myeloma UK) for use in small group of European countries. The Infopack provides information that patients may need to know following the diagnosis of myeloma and provides practical tips.

MPE will hold a webinar on ASH 2017 highlights in myeloma

Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2017. The talk will be given by Dr María Victoria Mateos, Associate Professor of Hematology and Consultant. Physician of the Haematology Department at the University Hospital of Salamanca, Spain.

Myeloma Patients Europe urges CHMP committee to approve plitidepsin for relapsed myeloma

Myeloma Patients Europe (MPE) has written to the Chair of the Committee for Human Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) to provide the patient viewpoint on the importance of plitidepsin (Aplidin®) for relapsed and refractory myeloma patients across Europe. We have outlined how important it is for patients across Europe to gain access to effective drugs that have new mechanisms of action.

Webinar “Science in patient advocacy”

As part of the Advocate Development Programme (ADP), MPE is organising an online webinar about science in patient advocacy. Although the webinars held within the ADP are usually open only to our ADP trainees, on this occasion we would like to invite to the webinar all our members and patient advocates interested in science. The webinar “Science in patient advocacy” will be given by Bettina Ryll, chair of the ESMO Patient Advocates Working Group (PAWG)…

ASH Annual Meeting 2017 is about to start

The 59th American Society of Hematology (ASH) Annual Meeting will take place from 9 – 12 December in Atlanta, Georgia, United States (US). Myeloma Patients Europe (MPE) will be attending the meeting, alongside thousands of leading doctors, researchers and patient advocates in the field of blood cancer (hematology). Below we explain ASH and the importance of the meeting to patient advocates.